Voronoi, Inc.

Voronoi, Inc.

KKRX:310210
101,100.00
KRW
+100.00
(+0.10%)
-3,807.18EPS
3.42TMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.25
15.26
25.38
520.97
1,166.07
574.39
- -
- -
417.6
- -
Basic EPS, GAAP
-178.89
-809.94
-4,219.58
-1,954.7
-1,190.71
-1,170.19
-2,401
-1,860
-2,374
-3,807.18
Free Cash Flow per Basic Share
-488.4
-1,370.76
-3,318.36
-1,371.7
-1,437.32
-993.04
-1,950.27
-1,727.14
-4,101.18
-5,093.89
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
478.74
1,544.73
917.14
1,855.58
463.86
2,295.31
4,786.22
3,696.48
5,661.92
3,773.53
Tangible Book Value per Share
70.9
760.62
-35.31
984.64
75.68
1,947.3
4,731.65
3,639.29
5,616.56
3,729.01
Basic Weighted Avg Shares
11
11
12
12
13
17
15
18
18
18
Sales/Revenue/Turnover
34
174
301
6,180
14,784
9,768
- -
- -
7,512
- -
Operating Margin (%)
-7,691.47
-6,492.25
-18,024.98
-437.21
-73.19
-182.88
- -
- -
-723.94
- -
Depreciation Expense
234
727
2,647
3,268
3,211
3,031
2,705
1,966
1,787
2,184
Net Income, GAAP
-1,882
-9,218
-50,003
-23,187
-15,096
-19,900
-36,848
-32,613
-42,706
-69,133
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-5,499.01
-5,307.5
-16,627.54
-375.2
-102.11
-203.73
- -
- -
-568.49
- -
Working Capital
3,951
12,157
-8,068
-5,322
571
35,342
48,807
49,685
140,411
95,889
LT Debt
- -
2,100
2,767
368
14,757
15,499
498
410
38,819
32,604
Total Equity
11,996
30,568
17,620
28,614
6,918
34,258
81,344
66,413
103,795
69,177
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-61.09
-272.37
-112.14
-87.28
-96.66
-63.75
-44.14
-50.18
-119.39

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
993
1,172
1,215
LT Borrowings
37,258
32,703
31,047
LT Finance Leases
1,562
1,746
1,556
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
18
18
Market Capitalization
3,987,237
5,627,962
3,422,608

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
148,308
131,803
107,229
Cash, Cash Equivalents & STI
135,679
118,825
93,513
Accounts Receivable, Net
22
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
7,898
11,779
11,340
Payables & Accruals
- -
- -
- -
ST Debt
993
1,172
1,215
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
98.95%
56.29%
Free Cash Flow
- -
45.34%
143.62%
Net Income, GAAP
- -
20.31%
30.95%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
3,350
4,140
22
7,512
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-385
-445.02
-525.65
-493.51
-1,860
2025
-785
-582.78
-767.36
-239.53
-2,374
2026
-1,202.32
-1,581.28
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Daekwon Kim
Full Time Employees
149
Sector
Health technology
Industry
Pharmaceuticals: major
Address
S-18, 32, Songdogwahak-ro Inchon South Korea 21984
IPO Date
Jun 24, 2022
Website
voronoi.io
Business
Voronoi, Inc. (310210.KQ) researches, develops, and commercializes small molecule kinase inhibitors and targeted protein degraders for oncology and immunology indications; its pipeline features VRN01, an oral leucine-rich repeat kinase 2 inhibitor for glioblastoma multiforme and pancreatic cancers; VRN07, VRN06, and VRN11, third-generation EGFR inhibitors for non-small cell lung cancer including EGFR C797S mutations and brain metastases; VRN08 and VRN10 for breast and HER2-positive solid tumors; VRN02 for rheumatoid arthritis and atopic dermatitis; VRN04-1 for autoimmune diseases; VRN04-2 for multiple sclerosis and amyotrophic lateral sclerosis; VRN13 for pulmonary arterial hypertension; and VRN14 for refractory solid cancers. The company leverages its proprietary VORONOMICS platform, integrating AI-driven drug discovery, in-vitro, in-vivo testing across six labs in three research centers, and high-throughput screening of over 550,000 compounds annually to accelerate candidate development from over 4.5 years to under one year. Founded in 2015 and headquartered in Incheon, South Korea, with an additional hub in Boston, Massachusetts, Voronoi operates primarily in South Korea and the United States, focusing on technology transfer of pre-clinical candidates and AI-based drug development platforms. In recent developments, Voronoi secured first-place ranking in small molecule drug patents under the Patent Cooperation Treaty in March 2025; announced positive early clinical efficacy data for VRN11 in low-dose treatment of EGFR C797S mutant non-small cell lung cancer at AACR 2025 in April; and received domestic Phase 1 IND approval for VRN10 targeting HER2-positive solid tumors from South Korea's Ministry of Food and Drug Safety in March 2025; the company also participates in the AACR-NCI-EORTC International Conference in Boston from October 22-26, 2025.